Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2007-05-15
2007-05-15
Parkin, Jeffrey S. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C435S005000, C435S006120
Reexamination Certificate
active
10519035
ABSTRACT:
The present invention is directed to the field of nucleic acid diagnostics and the identification of base variation in target nucleic acid sequences. More particularly, the present invention relates to the use of such genotypic characterization of a target population of HIV and the subsequent association, i.e., correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in drug development, i.e., drug discovery, drug design, drug modification, and therapy, treatment design, clinical management and diagnostic analysis.
REFERENCES:
patent: 327742 (1885-10-01), Uren
patent: 406985 (1991-01-01), None
patent: 428000 (1991-05-01), None
patent: 97/27332 (1997-07-01), None
patent: 97/27480 (1997-07-01), None
patent: WO 97/23719 (1997-07-01), None
patent: 99/67428 (1999-12-01), None
patent: 00/73511 (2000-12-01), None
patent: 00/78994 (2000-12-01), None
patent: 00/78996 (2000-12-01), None
patent: WO 01/79540 (2001-10-01), None
patent: 01/81624 (2001-11-01), None
patent: 01/95230 (2001-12-01), None
patent: 02/22076 (2002-03-01), None
patent: 02/33402 (2002-04-01), None
patent: 02/38792 (2002-05-01), None
patent: 02/083657 (2002-10-01), None
patent: 04/022523 (2004-03-01), None
Shafer et al. Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database, Jan. 1999, Nucleic Acids Research, vol. 27, No. 1, pp. 348-352.
Craig, et al. HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy 1998. AIDS vol. 12, pp. 1611-1618.
Shafer, et al. Highly active antiretroviral therapy for the treatment of infection with human immunodeficiency virus type 1, 1999. Biomedicine & Pharmacotherapy vol. 53, pp. 73-86.
Parikh, et al. Mutations in retroviral genes associated with drug resistance 2000. [online]. HIV Sequence Database [retrieved on Dec. 9, 2005]. Retrieved from the Internet: <URL://hiv-web.lanl.gov/content/hiv-db/REVIEWS/reviews.html>.
Abstract: International Congress on Drug Therapy in HIV Infection, vol. 12,Supplement 4, AIDS.online.com.
Abstract: Comprehensive HIV Drug Resistance Monitoring Using Rapid, High-Throughut Phenotypic and Geotypic Assays with Correlative Data Analysis. Poster Abstracts, OP3.4.
Condra, Jon ., et al. Genetic Correlates of InVivo Viral Resistance to Idivavir,a HumanImmunodefieiency Virus Thpe 1 Protease Inhibitor. Journal of Virology, Dec. 1996, pp. 8270-8276.
Guidance for Industry. U.S. Department of Health and Human Services, Food and Drug Administration.
Eastman, P. Scott, et al. Nonisotopic Hybridization Asay for Determinatin of Relative Amounts of Genotypic Human Immunodeficiency Virus Tpe 1 Zidovudine Resistance, Journal of Clinical Microbiology, Oct. 1995, pp. 2777-2780.
Eriksson, Bertil F.H., et al. Phosphorylation of 3′-Azido-2′,3′-Dideoxyuridine and Preferential Inhibition of Human and Simian Immunodeficiency Virus Reverse Transcriptases by its 5′-Triphosphate. Antimicrobial Agents ad Chemotherapy, Oct. 1989, pp. 1729-1734.
Fodor,Stephen P.A., et al. Multiplexed Biochemical Assays With Biological Chips. Nature, Aug. 5, 1993, vol. 364, pp. 555-556.
Harada, Shinji, et al. Infection of HTLV-III/LAV in HTLV-I-Carring Cells MT-2 andMT-4 andApplicationin a Plaque Assay. Department o Virology and Prasitology, Yamaguchi University, Japan, Aug. 9, 1985, p. 563-566.
Hertogs, Kurt, et al. A Rapid Method for Simultaneous Detection of Pheotpic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs. Antimicrobial Agents ad Chemotherapy, Feb. 1998, pp. 269-276.
Ibanex, Angela, et al. Human Immunodeficiency Virus Type 1 Population Bottleneck During Indinavir Theraphy Causes a Genetic Drift in the envquasispecies . . . Journal of General Virology, 2000, p. 85-95.
Konig, Herbert, et al. Azidothymidine Triphosphate Is an Inhibitor of Both Human Immunodeficiency Virus Type 1 Reverse Transcripatse and DNA Polymerase Gamma. Antimicrobial Agents and Chemotherapy, Dec. 1989, pp. 2109-2114.
Larder, Brendan A., et al. Zidovudine Resistance Predicted by Direct Detection of Mutations in DNA from HIV-infected Lymphocytes. AIDS, 1991, 5:137-144.
Larder, Brendan A., et al. HIV with a Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy. Reports, Mar. 31, 1980, pp. 1731-1734.
Lennerstrand, J., et al. A Method for Combined Immunoaffinity Purification and Assay of HIV-1 Reverse Transcriptase Activity Useful for Crude Samples. Analytical Biochemistry 235, 1996, pp. 141-152.
Matayoshi, Edmund D., et al. Novel Flurogenic Substrates for Assaying Retroviral Proteases by Resonance Energy Transfer. Science. vol. 247, pp. 954-958.
Miller, Veronica, et al. Patterns of Resistance and Cross-Resistance to Human Immunodeficiency Virus type 1 Reverse Transcriptase Inhibitors in Patents Treated with the Nonnucleoside Reverse Transcripatse Inhibitor Loviride. Antimicrobial Agents ad Chemotherapy, Dec. 1998, pp. 3123-3129.
Rusconi, Stefao, et al. Susceptibility to PNU-140690 (Tipranavir) of Human Immunodeficiency Virus Type 1 Isolates Derived from Patients with Multidrug Resistance to Other Protease Inhibitors. Antimicrobial Agents and Chemotherapy, May 2000, pp. 1328-1332.
Stuyver, Lieven, et al. Line Probe Assay for Rapid Detection of Drug-Selected Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcripatase Gene. Antimicrobial Agents and Chemotherapy, Feb. 1997, pp. 284-291.
Toth, Mihaly V., et al. A Simple, Continuous Flurometric Assay for HIV Protease. Int. J. Peptide Protein Res. 36, 1990, pp. 544-550.
Tyagi, Suresh C., et al. Continuous Assay of the Hydrolytic Activity of Human Immunodeficiency Virus-1 Protease. Analytical Biochemistry 200, pp. 143-145 (1992).
Tyagi, Sanjay, et al. Multicolor Molecular Beacons for Allele Discrimination. Nature Biotechnology, Jan. 1998, vol. 16, pp. 49-53.
Vasudevachari, M.B., et al. Emergence of Protease Inhibitor Resistance Mutations in Human Immunodeficiency Virus Type 1 Isolates from Patients and Rapid Screening Procedure for Their Detection. Antimicrobial Agents and Chemotherapy, Nov. 1996, pp. 2535-2541, vol. 40, No. 11.
Vergne, Lurence, et al. Genetic Diversity of Protease and Reverse Transcriptase Sequences in Non-Subtype-B Human Immunodeficiency Virus Type 1 Strains: Evidence of Many Minor Drug Resistance Mutations in Treatment-Naïve Patents. Journal of Clinical Microbiolog, Nov. 2000, p. 3919-3925, vol. 38, No. 11.
Wang, Gary T., et al. Design and Synthesis of New Fluorogenic HIV Protease Substrates Based on Resonance Energy Transfer. TetrahedronLetters, vol. 31, o. 45, pp. 6496-6496.
PCT Search Report dated Jan. 4, 2005, International Application No. PCT/EP 03/50280.
PCT Search Report dated Nov. 10, 2003,International Applcation No. PCT/EP 03/50277.
U.S. Appl. No. 10/519,436, filed Dec. 22, 2004.
U.S. Appl. No. 518,525, filed Dec. 22, 2004.
Azijn Hilde
De Bethune Marie-Pierre T. M. M. G
De Meyer Sandra
Humphrey Louise
Parkin Jeffrey S.
Ren Yunling
Tibotec Pharmaceuticals Ltd.
LandOfFree
Mutational profiles in HIV-1 protease correlated with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mutational profiles in HIV-1 protease correlated with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutational profiles in HIV-1 protease correlated with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3805954